Replies to post #218978 on Biotech Values

[DewDiligence]

Do ABBV/GILD have more pricing power with BMY and MRK not in market, and no competitors on horizon?

Naturally. ABBV’s CFO said as much on yesterday’s DB webcast, citing the newfound duopoly market.

[Rocky3]

Comments on HCV sales to date -https://www.investorvillage.com/smbd.asp?mb=2629&mn=11690&pt=msg&mid=18284160